Two-drug Immunotherapy May Produce Better Survival in Advanced Melanoma

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

February 23, 2024

Vol.50 No.08

Clinical Roundup

SWOG: Major pathologic response to neoadjuvant Keytruda in advanced melanoma trial exceeds 50%

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant Keytruda (pembrolizumab).

October 27, 2023

Vol.49 No.40

Drugs & Targets

FDA approves nivolumab for adjuvant treatment of stage 2B/C melanoma

FDA approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage 2B/C melanoma in patients 12 years and older.

October 20, 2023

Vol.49 No.39

Clinical Roundup

Nivolumab + ipilimumab more effective in immunotherapy-resistant melanoma than ipilimumab alone

A multicenter phase II clinical study conducted by the SWOG Cancer Research Network suggests that combination ipilimumab and nivolumab can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to PD-1 inhibitors.

September 15, 2023

Vol.49 No.34

Drugs & Targets

EC approves Opdivo in early stage melanoma

The European Commission approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage 2B or 2C melanoma who have undergone complete resection, based upon results from the CheckMate-76K trial.

September 08, 2023

Vol.49 No.33

Clinical Roundup

Moderna, Merck initiate phase III trial evaluating V940 + Keytruda in melanoma indication

Merck and Moderna have initiated a phase III randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Keytruda (pembrolizumab) as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma.

July 28, 2023

Vol.49 No.30

Two-drug Immunotherapy May Produce Better Survival in Advanced Melanoma

YOU MAY BE INTERESTED IN

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

SWOG: Major pathologic response to neoadjuvant Keytruda in advanced melanoma trial exceeds 50%

FDA approves nivolumab for adjuvant treatment of stage 2B/C melanoma

Nivolumab + ipilimumab more effective in immunotherapy-resistant melanoma than ipilimumab alone

EC approves Opdivo in early stage melanoma

Moderna, Merck initiate phase III trial evaluating V940 + Keytruda in melanoma indication

Renew today!

Subscriber content

Login